A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening

May 21, 2026 updated by: Memorial Sloan Kettering Cancer Center

Pilot Study of a Dedicated MR of the Pancreas: Improving Screening for Patients at High Risk for Pancreas Cancer

The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

79

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Richard Kinh Gian Do, MD, PhD
  • Phone Number: 212-639-8591
  • Email: dok@mskcc.org

Study Contact Backup

Study Locations

  • United States
    • New Jersey
      • Basking Ridge, New Jersey, United States, 07920
        • Recruiting
        • Memorial Sloan Kettering Basking Ridge (Consent Only)
        • Contact:
          • Richard Kinh Gian Do, MD, PhD
          • Phone Number: 212-639-8591
      • Middletown, New Jersey, United States, 07748
        • Recruiting
        • Memorial Sloan Kettering Monmouth (Consent Only)
        • Contact:
          • Richard Kinh Gian Do, MD, PhD
          • Phone Number: 212-639-8591
      • Montvale, New Jersey, United States, 07645
        • Recruiting
        • Memorial Sloan Kettering Bergen (Consent Only)
        • Contact:
          • Richard Kinh Gian Do, MD, PhD
          • Phone Number: 212-639-8591
    • New York
      • Commack, New York, United States, 11725
        • Recruiting
        • Memorial Sloan Kettering Suffolk-Commack (Consent Only)
        • Contact:
          • Richard Kinh Gian Do, MD, PhD
          • Phone Number: 212-639-8591
      • Harrison, New York, United States, 10604
        • Recruiting
        • Memorial Sloan Kettering Westchester (Consent Only)
        • Contact:
          • Richard Kinh Gian Do, MD, PhD
          • Phone Number: 212-639-8591
      • New York, New York, United States, 10065
        • Recruiting
        • Memorial Sloan Kettering Cancer Center (All Protocol Activites)
        • Contact:
          • Richard Kinh Gian Do, MD, PhD
          • Phone Number: 212-639-8591
      • Uniondale, New York, United States, 11553
        • Recruiting
        • Memorial Sloan Kettering Nassau (Consent Only)
        • Contact:
          • Richard Kinh Gian Do, MD, PhD
          • Phone Number: 212-639-8591

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Investigators will conduct this pilot study in high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry

Description

Inclusion Criteria:

  • Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual
  • Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer
  • Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2
  • Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+

For this pilot MRP study, we will additionally apply the following Criteria:

  • Consents to follow-up contact
  • US residents
  • Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass)
  • No metallic artifacts covering the pancreas on prior MRCP
  • Scheduled for endoscopic ultrasound
  • No new contraindications for MRI (e.g. new MR unsafe device)
  • No history of claustrophobia or use of anxiolytic on prior MRI
  • No history of abdominal surgery that may affect interpretation of either EUS or MR
  • No medical conditions that confers increased and/or unacceptable risk for anesthesia

We will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in ~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget.

  • Documentation of Disease

    o No pathologic confirmation of disease is necessary

  • Definition of Disease N/A
  • Not Pregnant and Not Nursing
  • Required Organ Function N/A

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Participants at high risk for pancreas ductal adenocarcinoma
Participants will be high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry
Diagnostic test: MRI
Participants will undergo a single MRI of the abdomen without contrast
Other Names:
  • Magnetic Resonance CholangioPancreatography, MRP
Diagnostic test: Endoscopic ultrasound
EUS will be scheduled the same day or within 2 weeks prior to MRP
Other Names:
  • EUS

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Compare image quality of novel high-resolution magnetic resonance pancreas (MRP) to conventional MRCP
Time Frame: Up to 3 years
Develop and pilot a focused high-resolution magnetic resonance pancreas (MRP) exam to help facilitate early pancreatic cancer detection in high-risk individuals. Image quality for T1, T2, and DWI sequences performed on the novel MRP exam will be compared to conventional MRCP performed in the same participants.
Up to 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

National Institutes of Health (NIH)

Investigators

  • Principal Investigator: Richard Kinh Gian Do, MD, PhD, Memorial Sloan Kettering Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 20, 2026

Primary Completion (Estimated)

May 20, 2028

Study Completion (Estimated)

May 20, 2028

Study Registration Dates

First Submitted

May 21, 2026

First Submitted That Met QC Criteria

May 21, 2026

First Posted (Actual)

May 28, 2026

Study Record Updates

Last Update Posted (Actual)

May 28, 2026

Last Update Submitted That Met QC Criteria

May 21, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 26-174

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

• Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pancreatic Cancer

Clinical Trials on MRI

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe